131 related articles for article (PubMed ID: 37254045)
21. Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer.
Kano K; Yamada T; Yamamoto K; Komori K; Watanabe H; Hara K; Shimoda Y; Maezawa Y; Fujikawa H; Aoyama T; Tamagawa H; Yamamoto N; Cho H; Shiozawa M; Yukawa N; Yoshikawa T; Morinaga S; Rino Y; Masuda M; Ogata T; Oshima T
Ann Surg Oncol; 2020 Oct; 27(11):4235-4247. PubMed ID: 32424582
[TBL] [Abstract][Full Text] [Related]
22. Tumor size ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
Tsutsuyama M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2020 Jan; 44(1):194-201. PubMed ID: 31552460
[TBL] [Abstract][Full Text] [Related]
23. A prospective clinicopathologic study of venous invasion in colorectal cancer.
Shirouzu K; Isomoto H; Kakegawa T; Morimatsu M
Am J Surg; 1991 Sep; 162(3):216-22. PubMed ID: 1928581
[TBL] [Abstract][Full Text] [Related]
24. Risk Factors and Risk Scores for Predicting Early Recurrence After Curative Gastrectomy in Patients with Stage III Gastric Cancer.
Wakatsuki K; Matsumoto S; Migita K; Kunishige T; Nakade H; Miyao S; Sho M
J Gastrointest Surg; 2020 Aug; 24(8):1758-1769. PubMed ID: 31325135
[TBL] [Abstract][Full Text] [Related]
25. [Value of preoperative abdominal contrast-enhanced multiple-row detector computed tomography in predicting the postoperative 1-year disease-free survival for gastric cancer].
Feng C; Cheng J; Xiang H; Hong N; Ye Y; Wang Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1059-1064. PubMed ID: 30269328
[TBL] [Abstract][Full Text] [Related]
26. Pathological tumor infiltrative pattern and sites of initial recurrence in stage II/III gastric cancer: Propensity score matching analysis of a multi-institutional dataset.
Nakagawa N; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Cancer Med; 2018 Dec; 7(12):6020-6029. PubMed ID: 30411544
[TBL] [Abstract][Full Text] [Related]
27. Retrospective Analysis of Real-Life Data Evaluating the Optimal Time Between Gastrectomy and Adjuvant Chemotherapy in Resected Gastric Cancer.
Yücel KB; Sütcüoğlu O; Yazıcı O; Özet A; Özdemir N
J Gastrointest Cancer; 2023 Dec; 54(4):1268-1275. PubMed ID: 36821038
[TBL] [Abstract][Full Text] [Related]
28. [The value of spleen density in predicting prognosis of patients with gastric cancer after curative gastrectomy].
Li S; Ma PF; Zhang JL; Cao YH; Liu CY; Zhang XJ; Li ZY; Xue YW; Zhao YZ
Zhonghua Yi Xue Za Zhi; 2021 Sep; 101(34):2703-2709. PubMed ID: 34510877
[No Abstract] [Full Text] [Related]
29. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
30. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer.
Kambara Y; Miyake H; Nagai H; Yoshioka Y; Shibata K; Asai S; Yuasa N
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1918-1924. PubMed ID: 32814681
[TBL] [Abstract][Full Text] [Related]
31. Preoperative CA19-9 is a prognostic factor in pT3N0 gastric cancer patients undergoing curative resection.
Maruyama T; Akashi Y; Hakoda H; Sako A; Ueda K; Kato S; Azuma K; Kaneko Y; Ikeguchi A; Nagai S; Oda T
Langenbecks Arch Surg; 2022 Sep; 407(6):2273-2279. PubMed ID: 35551467
[TBL] [Abstract][Full Text] [Related]
32. Stage-specific difference in timing and pattern of initial recurrence after curative surgery for gastric cancer.
Kim JH; Lee HH; Seo HS; Jung YJ; Park CH
Surg Oncol; 2019 Sep; 30():81-86. PubMed ID: 31500791
[TBL] [Abstract][Full Text] [Related]
33. Proposal for a clinicopathological prognostic score for resected gastric cancer patients.
DIaz Del Arco C; Estrada Muñoz L; Molina Roldán E; Ortega Medina L; García Gómez de Las Heras S; Chávez Á; Fernández Aceñero M
Saudi J Gastroenterol; 2021; 27(1):44-53. PubMed ID: 33047677
[TBL] [Abstract][Full Text] [Related]
34. Poor prognostic subgroup in T3N0 stage IIA gastric cancer, suggesting an indication for adjuvant chemotherapy.
Imamura T; Komatsu S; Ichikawa D; Kubota T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Morimura R; Murayama Y; Kuriu Y; Ikoma H; Nakanishi M; Sakakura C; Otsuji E
J Surg Oncol; 2015 Feb; 111(2):221-5. PubMed ID: 25327711
[TBL] [Abstract][Full Text] [Related]
35. Differences in risk factors between patterns of recurrence in patients after curative resection for advanced gastric carcinoma.
Nakanishi Y; Ohara M; Domen H; Shichinohe T; Hirano S; Ishizaka M
World J Surg Oncol; 2013 May; 11():98. PubMed ID: 23683476
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy.
Tanaka H; Kanda M; Shimizu D; Tanaka C; Inokawa Y; Hattori N; Hayashi M; Nakayama G; Kodera Y
J Gastroenterol; 2022 Sep; 57(9):640-653. PubMed ID: 35726075
[TBL] [Abstract][Full Text] [Related]
37. CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer.
Soeno T; Katoh H; Ishii S; Ushiku H; Hosoda K; Hiki N; Watanabe M; Yamashita K
J Surg Res; 2020 Jan; 245():552-563. PubMed ID: 31472311
[TBL] [Abstract][Full Text] [Related]
38. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
39. Tumor Deposit Is an Independent Factor Predicting Early Recurrence and Poor Prognosis in Gastric Cancer.
Fujikawa K; Omori T; Shinno N; Hara H; Yamamoto M; Yasui M; Matsuda C; Wada H; Nishimura J; Haraguchi N; Akita H; Ohue M; Miyata H
J Gastrointest Surg; 2023 Jul; 27(7):1336-1344. PubMed ID: 37014588
[TBL] [Abstract][Full Text] [Related]
40. Survival times are similar among patients with peritoneal, hematogenous, and nodal recurrences after curative resections for gastric cancer.
Sawaki K; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Cancer Med; 2020 Aug; 9(15):5392-5399. PubMed ID: 32515147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
